<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514774</url>
  </required_header>
  <id_info>
    <org_study_id>00001927</org_study_id>
    <nct_id>NCT00514774</nct_id>
  </id_info>
  <brief_title>Ursodiol in Huntington's Disease</brief_title>
  <acronym>UDCA-HD</acronym>
  <official_title>Ursodiol in Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huntington Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntington Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic
      acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is
      processed by the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Huntington's disease is an inherited neurodegenerative disease that causes a movement
      disorder, dementia, and psychiatric and behavioral disturbance in affected individuals.

      Tauroursodeoxycholic acid (TUDCA) is a bile acid synthesized in the liver by the conjugation
      of taurine to ursodeoxycholic acid (UDCA). It is thought to function as an anti-apoptotic
      agent in HD, evidenced by studies in toxic cell models and both toxic and transgenic rodent
      models of the disease.

      Ursodiol is a commercially-available exogenous form of UDCA, the precursor of TUDCA. Although
      the compound has an established dosing, safety, tolerability and efficacy profile in patients
      with hepatobiliary disorders, gaps exist in the understanding of the pharmacokinetics /
      pharmacodynamics of the compound, particularly in patients with normal gastrointestinal
      function, and no human data exist for its therapeutic use in neurodegenerative disorders. The
      specific aims of this study are:

        1. To establish whether treatment with the drug ursodiol will result in measurable levels
           of its bile acid metabolites in serum and CSF at standard oral doses; and whether a
           dose-response can be detected using these measures.

        2. To establish a preliminary safety and tolerability profile of the drug in subjects with
           HD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures (complete blood count, chemistry profile, electrocardiogram, urinalysis)</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability measures (adverse event severity)</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic measures (Serum and CSF levels of bile acids)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodiol</intervention_name>
    <description>ursodiol 300 mg twice daily for study days 0 through 28
ursodiol 600mg twice daily on study days 0 through 28</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Ursodeoxycholic acid</other_name>
    <other_name>UDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 600mg twice daily for study days 0 through 28</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects will be age 18 or older

          -  All subjects will have manifest Huntington disease determined by clinical exam plus
             either documented prior DNA testing for the HD gene or a documented family history of
             the disease

        Exclusion Criteria:

          -  Subjects taking oral contraceptives, cholestyramine, colestipol, or aluminum-based
             antacids will be excluded

          -  Subjects with known allergy or other contraindication to the study drug will be
             excluded

          -  Subjects with bleeding diathesis, or on coumadin or mandatory aspirin will be excluded

          -  Subjects with unstable medical or psychiatric illness will be excluded

          -  Subjects with clinically significant lab / EKG abnormalities at screening will be
             excluded

          -  Subjects who are currently pregnant or breastfeeding will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penelope Hogarth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.huntington-study-group.org/</url>
    <description>Official website for the Huntington Study Group</description>
  </link>
  <reference>
    <citation>Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. Epub 2002 Jul 29.</citation>
    <PMID>12149470</PMID>
  </reference>
  <reference>
    <citation>Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60.</citation>
    <PMID>11573988</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Penelope Hogarth, MD</name_title>
    <organization>Oregon Health &amp; Science University</organization>
  </responsible_party>
  <keyword>Huntington chorea</keyword>
  <keyword>chorea</keyword>
  <keyword>hereditary</keyword>
  <keyword>tauroursodeoxycholic acid</keyword>
  <keyword>ursodeoxycholic acid</keyword>
  <keyword>TUDCA</keyword>
  <keyword>UDCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

